Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis
Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis
Objectives: Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours, including gastroenteropancreatic neuroendocrine neoplasms (NENs), lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary NENs is controversial. This systematic review sought to assess whether Ki-67 is a prognostic biomarker in lung NENs and, if feasible, proceed to a meta-analysis.
Research, design and methods: Medline (Ovid), Embase, Scopus and the Cochrane library were searched for studies published prior to 28 February 2019 and investigating the role of Ki-67 in lung NENs. Eligible studies were those that included more than 20 patients and provided details of survival outcomes, namely, HRs with CIs according to Ki-67 percentage. Studies not available as a full text or without an English manuscript were excluded. This study was prospectively registered with PROSPERO.
Results: of 11 814 records identified, seven studies met the inclusion criteria. These retrospective studies provided data for 1268 patients (693 TC, 281 AC, 94 large cell neuroendocrine carcinomas and 190 small cell lung carcinomas) and a meta-analysis was carried out to estimate a pooled effect. Random effects analyses demonstrated an association between a high Ki-67 index and poorer overall survival (HR of 2.02, 95% CI 1.16 to 3.52) and recurrence-free survival (HR 1.42; 95% CI 1.01 to 2.00).
Conclusion: this meta-analysis provides evidence that high Ki-67 labelling indices are associated with poor clinical outcomes for patients diagnosed with pulmonary NENs. This study is subject to inherent limitations, but it does provide valuable insights regarding the use of the biomarker Ki-67, in a rare tumour.
Prospero registration number: CRD42018093389.
endocrine tumours, pathology, respiratory tract tumours
e041961
Naheed, Salma
fed1da9a-e9df-4a42-9e1c-c1e24c0e38fd
Holden, Chloe
2a5d1641-3e7e-4537-96f0-1a3a011af340
Tanno, Lulu
b1e0f618-9918-428a-88c7-52846c2b8a64
Pattini, Linda
28daa161-9608-4592-9319-61d9dd65cfa9
Pearce, Neil W
bbd2fe84-c835-4c73-aa40-ba5fceefa690
Green, Bryan
54c99b90-e0b5-42b0-9b5d-456c770d60b0
Jaynes, Eleanor
dae2d9a2-5cda-46a4-aa7e-4d04e495fe65
Cave, Judith
60c67e39-121a-49ca-8594-93e8e456464f
Ottensmeier, Christian H
42b8a398-baac-4843-a3d6-056225675797
Pelosi, Giuseppe
ff759f2f-e348-46b2-bec5-da656ac574d9
3 March 2022
Naheed, Salma
fed1da9a-e9df-4a42-9e1c-c1e24c0e38fd
Holden, Chloe
2a5d1641-3e7e-4537-96f0-1a3a011af340
Tanno, Lulu
b1e0f618-9918-428a-88c7-52846c2b8a64
Pattini, Linda
28daa161-9608-4592-9319-61d9dd65cfa9
Pearce, Neil W
bbd2fe84-c835-4c73-aa40-ba5fceefa690
Green, Bryan
54c99b90-e0b5-42b0-9b5d-456c770d60b0
Jaynes, Eleanor
dae2d9a2-5cda-46a4-aa7e-4d04e495fe65
Cave, Judith
60c67e39-121a-49ca-8594-93e8e456464f
Ottensmeier, Christian H
42b8a398-baac-4843-a3d6-056225675797
Pelosi, Giuseppe
ff759f2f-e348-46b2-bec5-da656ac574d9
Naheed, Salma, Holden, Chloe, Tanno, Lulu, Pattini, Linda, Pearce, Neil W, Green, Bryan, Jaynes, Eleanor, Cave, Judith, Ottensmeier, Christian H and Pelosi, Giuseppe
(2022)
Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis.
BMJ Open, 12 (3), .
(doi:10.1136/bmjopen-2020-041961).
Abstract
Objectives: Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours, including gastroenteropancreatic neuroendocrine neoplasms (NENs), lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary NENs is controversial. This systematic review sought to assess whether Ki-67 is a prognostic biomarker in lung NENs and, if feasible, proceed to a meta-analysis.
Research, design and methods: Medline (Ovid), Embase, Scopus and the Cochrane library were searched for studies published prior to 28 February 2019 and investigating the role of Ki-67 in lung NENs. Eligible studies were those that included more than 20 patients and provided details of survival outcomes, namely, HRs with CIs according to Ki-67 percentage. Studies not available as a full text or without an English manuscript were excluded. This study was prospectively registered with PROSPERO.
Results: of 11 814 records identified, seven studies met the inclusion criteria. These retrospective studies provided data for 1268 patients (693 TC, 281 AC, 94 large cell neuroendocrine carcinomas and 190 small cell lung carcinomas) and a meta-analysis was carried out to estimate a pooled effect. Random effects analyses demonstrated an association between a high Ki-67 index and poorer overall survival (HR of 2.02, 95% CI 1.16 to 3.52) and recurrence-free survival (HR 1.42; 95% CI 1.01 to 2.00).
Conclusion: this meta-analysis provides evidence that high Ki-67 labelling indices are associated with poor clinical outcomes for patients diagnosed with pulmonary NENs. This study is subject to inherent limitations, but it does provide valuable insights regarding the use of the biomarker Ki-67, in a rare tumour.
Prospero registration number: CRD42018093389.
Text
e041961.full
- Version of Record
More information
Accepted/In Press date: 8 October 2021
Published date: 3 March 2022
Keywords:
endocrine tumours, pathology, respiratory tract tumours
Identifiers
Local EPrints ID: 456479
URI: http://eprints.soton.ac.uk/id/eprint/456479
ISSN: 2044-6055
PURE UUID: e7ccb4ea-f049-437f-9d03-506473b8fb9b
Catalogue record
Date deposited: 03 May 2022 16:51
Last modified: 05 Jun 2024 19:32
Export record
Altmetrics
Contributors
Author:
Salma Naheed
Author:
Chloe Holden
Author:
Lulu Tanno
Author:
Linda Pattini
Author:
Neil W Pearce
Author:
Bryan Green
Author:
Eleanor Jaynes
Author:
Judith Cave
Author:
Giuseppe Pelosi
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics